Boston Scientific Corporation (BSX) Stock Analysis 2026
BriMind AI Score
ProprietaryScore based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.
BriMind 1-Year Price Target
BriMind AI combines DCF, momentum, and analyst consensus to project a 12-month price target.
AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →
About Boston Scientific Corporation
Boston Scientific is one of the world's largest medical device companies, focused on minimally invasive procedures across cardiology, rhythm management, endoscopy, urology, and neuromodulation. Key products include drug-eluting stents, EP (electrophysiology) catheters for treating heart arrhythmias, intravascular ultrasound (IVUS), and the WATCHMAN device (left atrial appendage closure to prevent stroke in atrial fibrillation patients). The company has transformed from a stent-heavy business to a diversified medical device platform.
How Boston Makes Money
Boston Scientific earns through selling single-use and capital medical devices to hospitals, clinics, and ambulatory surgical centers. Products range from consumable EP catheters (~$500-2,000 each) used in every ablation procedure to high-value capital equipment like mapping/ablation systems ($200,000+). The company sells direct in most markets, with strong relationships with interventional cardiologists, electrophysiologists, and gastroenterologists. Recurring device usage in growing procedural volumes drives revenue.
Boston Revenue & Profitability Breakdown
This chart shows how Boston's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.
Key Financial Metrics
A snapshot of the company's valuation, growth, profitability, and financial health. Key things to look at: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business — companies with strong FCF can buy back shares, pay dividends, or invest; Debt/Equity shows how leveraged the company is (high debt can be risky); Return on Equity tells you how efficiently the company generates profit from shareholders' money.
Wall Street Analyst Consensus
Professional analysts at investment banks set 12-month price targets after researching the company's earnings, competitive position, and industry trends. Strong Buy / Buy means the majority expect meaningful upside. Hold means analysts see fair value near the current price — not a sell signal, but limited near-term upside expected. The mean target is the average of all analyst price targets; the range shows where the most optimistic and most cautious analysts stand.
BSX Investment Case: Bull vs Bear
Every investment has two sides. The bull case outlines the key reasons the stock could outperform — competitive advantages, growth catalysts, and market tailwinds. The bear case highlights the most significant risks that could cause the investment to underperform. Good investors read both sides carefully before deciding. A strong bull case with manageable bear risks typically makes for a more compelling investment.
Bull Case (Reasons to Buy)
- Electrophysiology is one of the fastest-growing medical device markets — AF (atrial fibrillation) prevalence is rising with aging populations, and new pulsed field ablation (PFA) technology is capturing rapid market share.
- WATCHMAN LAA closure has been growing rapidly as a stroke prevention alternative for AF patients who can't tolerate blood thinners — a large, underpenetrated indication.
- Boston Scientific's global commercial infrastructure lets it deploy new products (like pulsed field ablation) across 130+ countries quickly, leveraging existing hospital relationships.
- Diversified procedure exposure reduces the risk of any single product's competitive erosion on total revenue.
Bear Case (Key Risks)
- Pulsed field ablation competition: while BSX was a PFA pioneer with FARAPULSE, competitors (J&J, Medtronic, Biosense Webster) are now launching or planning PFA catheters.
- Cardiac stent and legacy businesses face ongoing pricing pressure as these markets mature and more procedure options compete for cases.
- Medical device reimbursement changes or hospital capex constraints could delay adoption of new procedures that require new capital equipment.
- Integration execution risk from multiple acquisitions — BSX has been an active acquirer and failed integrations have historically been a weakness.
What to Watch: BSX Key Metrics
BSX Stock — Frequently Asked Questions
Compare BSX with Peers
Unlock the Full BSX Analysis
Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.